Horse Chestnut (Aesculus hippocastanum)

Table of Contents

1. What Horse Chestnut Is
2. From Balkan Ravines to European Parks
3. The Extract Is Not the Seed
4. The Active Compounds
5. What the Evidence Shows for Chronic Venous Insufficiency
6. The Compression-Stocking Trial
7. Where It Sits Among Venoactive Treatments
8. Haemorrhoids, Bruises and Other Uses
9. Laboratory Research Beyond Veins
10. Doses Used in Trials and Monographs
11. Safety Findings
12. Who the Research Raises Concerns For
13. The Bottom Line
14. Deep-Dive Articles
15. External Sources
16. Key Research Papers
17. Connections
18. Featured Videos

What Horse Chestnut Is

Aesculus hippocastanum is a large deciduous tree that can grow to around 39 metres tall, with big leaves made of five to seven leaflets spread like the fingers of a hand, and upright candle-shaped clusters of white flowers in spring. According to the European Commission's forest-tree atlas, it is the only Aesculus species native to Europe, and its wild range is surprisingly small: a few mountain ravines in Greece, Albania and North Macedonia, plus a separate pocket in Bulgaria. Everywhere else — across the parks, gardens and avenues of Europe and beyond — it is planted.

The fruit is a green husk with widely spaced spikes, usually holding a single large, round, shiny brown seed with a pale scar on one side. That seed is the conker. It looks like an edible sweet chestnut, but the two trees are not closely related: sweet chestnuts belong to Castanea, in the beech family. The US poison-control service describes the practical differences: edible chestnut husks are densely spiny and look furry, hold several nuts with a pointed tip, and taste starchy; horse chestnut husks have sparser spikes, usually hold one round nut, and the nut is very bitter.

The same tree family includes the North American buckeyes. The National Library of Medicine's LiverTox reference notes that horse chestnut is not the same as the California or Ohio buckeye (Aesculus californica and Aesculus glabra), which are different species. The name "horse chestnut" is usually traced to the use of the seeds as horse feed, which is the origin the European forest atlas gives.

Back to Table of Contents

From Balkan Ravines to European Parks

The tree's spread across Europe is recent and well documented. The European forest atlas records that in 1557 seeds of uncertain origin were brought from Turkey to Prague, beginning its cultivation in Europe. The European Medicines Agency's 2012 assessment report on horse chestnut bark adds that the tree was described in 1565 by the Italian physician-botanist Mattioli, reached France in 1615, and spread to most of Europe during the 18th century.

Early medicinal use focused on the bark rather than the seed. The same EMA report describes bark being tried in 1720 as a fever remedy and a substitute for cinchona (the source of quinine) — a use later abandoned — and as an astringent for diarrhoea. Bark preparations for varicose veins and haemorrhoids appear in French sources, and horse chestnut bark entered the French Pharmacopoeia in 1866. That report found no clinical studies of the bark at all; its uses rest on tradition.

The modern medicine came later and from the seed. The EMA's 2020 seed assessment report states that dry ethanol extracts of the seed have been used in Europe for chronic venous insufficiency since 1968. Folk use continues alongside it: the European forest atlas notes that decoctions of bark and leaves are still used in folk medicine in Albania, Kosovo and central Italy for circulation and rheumatic complaints.

The wild tree itself is in trouble. The atlas reports fewer than 2,500 mature trees left in the native range, under pressure from a leaf-mining moth (Cameraria ohridella) that strips the leaves in midsummer, plus logging, road building, pollution and fire. It lists the species as vulnerable in Greece and Bulgaria and near-threatened at European scale. Medicinal seed comes from planted trees.

Back to Table of Contents

The Extract Is Not the Seed

Almost every positive finding about horse chestnut refers to one kind of product: a dried alcohol-and-water extract of the seed, standardised so that each dose delivers a fixed amount of aescin. The EMA assessment report describes the extract used in 14 of the trials in the main systematic review as capsules of 240–290 mg of dry extract containing 50 mg of aescin, taken twice a day. Researchers abbreviate this as HCSE (horse chestnut seed extract).

Two authorities describe the relationship between that extract and the poisonous raw plant in slightly different words, and both are worth reading closely:

• The US National Center for Complementary and Integrative Health (NCCIH) states that the raw seeds, bark, flowers and leaves are unsafe when taken by mouth because they contain a toxic component, esculin, and that standardised seed extracts from which this component has been removed are likely safe for short-term use.
• The European Medicines Agency's seed assessment report states that coumarin compounds such as aesculin (esculin) and fraxetin occur in other parts of the tree but not in the seed or seed shell, and it records that one form of aescin, β-aescin, can break open red blood cells in laboratory tests (haemolytic activity) while another form, cryptoaescin, does not.

The practical message is the same from both: the medicine is a processed, measured extract, and eating conkers or brewing bark or leaves is a different and hazardous exposure. The chemistry of exactly which compound does what in a raw-seed poisoning is less tidy than popular summaries suggest. The deep-dive page Raw Seed Poisoning and Esculin sets the sources side by side.

Back to Table of Contents

The Active Compounds

Aescin (escin). Aescin is not one molecule but a mixture of triterpenoid saponins — soap-like compounds built on a five-ring carbon skeleton with sugar chains attached. A 2023 review describes β-escin as an oleanane-type pentacyclic triterpenoid saponin extracted from the seeds. Aescin is treated as the marker of the extract, and Sirtori's 2001 review calls it the major active principle of the tree. The EMA is more cautious: its 2020 report says the data supporting aescin as the compound responsible for the extract's effect are "very weak," although the extracts used in most trials were standardised on it.

Flavonoids, sterols and starch. The EMA report lists small amounts of flavonoids (about 0.3%, mainly quercetin and kaempferol glycosides), sterols, essential oil, and a high proportion of starch (30–60%) in the seed.

Coumarins: esculin and fraxin. The bark is rich in coumarin derivatives — up to 7% according to the EMA bark report — chiefly esculin (a sugar-bound form of esculetin) and fraxin. Esculin has been studied in its own right in mice. Coumarin-type compounds are the reason some reviews raise a theoretical question about bleeding with blood thinners, discussed under safety below.

The deep-dive page Aescin: How It Works covers what is known about the mechanism, and how much of it comes from animals and isolated tissue rather than people.

Back to Table of Contents

What the Evidence Shows for Chronic Venous Insufficiency

Chronic venous insufficiency (CVI) happens when the one-way valves in the leg veins stop closing properly, so blood pools in the lower legs. The result is swelling around the ankles, a heavy or tired feeling, aching, itching, night cramps, and in later stages skin changes and ulcers. A 2024 review of herbal drugs for venous disease notes that chronic venous disease affects somewhere between 20% and 80% of the population worldwide, depending on how it is defined.

The main summary of the trials is the Cochrane review by Pittler and Ernst, first published in 2002 and last updated in 2012. Its 2012 findings:

• Leg pain was measured in seven placebo-controlled trials. Six reported a significant reduction with the extract compared with placebo; the seventh reported improvement compared with baseline. One trial with usable data found a difference of 42.4 mm on a 100 mm pain scale.
• Leg volume — a direct measure of swelling, taken by lowering the leg into water and measuring what it displaces — was pooled across six trials with 502 participants. The extract reduced leg volume by an average of 32.1 ml more than placebo (95% confidence interval 13.49 to 50.72 ml).
• One trial suggested the extract may be as effective as compression stockings.
• Adverse events were usually mild and infrequent.

The reviewers concluded that the extract appears to be an efficacious and safe short-term treatment, but added that "several caveats exist" and that larger, definitive trials are required. The EMA assessment report fills in the caveats: across the 17 trials, 1,443 people took part; trials ranged from 20 to 286 participants and eleven had fewer than 50; and they lasted between 2 and 16 weeks. A separate 2002 meta-analysis by Siebert and colleagues, which also pooled three large observational studies of 10,725 patients, reached a similar conclusion, found a leg-volume reduction of 46.4 ml against placebo, and found insufficient evidence of an effect on leg heaviness or calf cramps.

A 2022 review for family doctors summarised the evidence as moderate quality for improving swelling from CVI, the same grade it gave to butcher's broom (Ruscus) extract. The full trial-by-trial picture, including how the pooled estimate shrank as more trials were added, is on the deep-dive page Chronic Venous Insufficiency Evidence.

Back to Table of Contents

The Compression-Stocking Trial

The trial most often quoted is the 1996 Lancet study by Diehm and colleagues. It randomised 240 people with chronic venous insufficiency to one of three arms for 12 weeks: class II compression stockings, a horse chestnut seed extract providing 50 mg aescin twice daily, or placebo. The design was partially blinded (it is impossible to blind someone to wearing a stocking).

Lower-leg volume in the more affected leg fell by an average of 43.8 ml with the extract (95 people) and 46.7 ml with compression (99 people), and rose by 9.8 ml with placebo (46 people). Both treatments beat placebo, and the authors' statistical test found the two treatments equivalent. The paper itself carries an important qualification: in its design, compression "could not be proven as standard" for reducing swelling in the statistical test procedure. Both treatments were well tolerated. The trial prompted published letters in reply in the same journal.

What the trial does not show matters as much. It measured swelling over 12 weeks. It did not compare the two approaches for preventing ulcers, healing ulcers, or long-term outcomes. Reviews of post-thrombotic syndrome describe compression stockings as the cornerstone of management, and a 2022 review for family doctors describes compression as effective for most causes of swelling.

Back to Table of Contents

Where It Sits Among Venoactive Treatments

Horse chestnut extract belongs to a group of products that European doctors call venoactive drugs: plant-derived compounds such as micronised purified flavonoid fraction (a diosmin–hesperidin mixture), Ruscus extract, rutosides, and Centella asiatica (gotu kola) extract. A 2025 review graded this whole class using a standard evidence scale. It found that the micronised flavonoid fraction and a Ruscus combination had the highest-quality evidence for symptoms and swelling, and that for venous leg ulcers the micronised flavonoid fraction, sulodexide and pentoxifylline had the strongest evidence. Horse chestnut was not among the top-graded products in that abstract.

Older head-to-head trials summarised in the 1998 systematic review by Pittler and Ernst found horse chestnut extract and O-(β-hydroxyethyl)-rutosides (a semi-synthetic flavonoid drug) about equally effective. For a related condition, post-thrombotic syndrome — the long-term leg swelling and pain that follows a deep-vein clot in more than one in three patients — reviews by Kahn describe aescin and rutosides as possibly providing short-term relief of symptoms, while compression stockings remain the cornerstone.

Pages on several of the comparators: Hesperidin and diosmin for veins, Rutin for veins and capillaries, and Gotu Kola for venous insufficiency.

Back to Table of Contents

Haemorrhoids, Bruises and Other Uses

Beyond leg veins, horse chestnut has a long list of traditional and modern uses, with very uneven evidence behind them.

• Haemorrhoids. Haemorrhoids are swollen veins, so the venous logic carries over. Sirtori's 2001 review describes aescin as having shown clinically significant activity in haemorrhoids, and the EMA bark report lists traditional bark preparations for haemorrhoidal symptoms in France and Spain. No randomised trial of horse chestnut for haemorrhoids appears among the records reviewed for this page.
• Bruises and swelling after injury. The EMA accepts topical horse chestnut seed preparations as traditional herbal medicines "for relief of signs of bruises, such as local oedema and haematoma" — a registration based on long use, not trials. A 2019 review reports that an aescin gel showed efficacy in blunt trauma injuries.
• Swelling after surgery or trauma. Injectable sodium aescinate is used clinically in China for swelling after trauma or operations, according to a 2008 paper. That is an injected drug, not a supplement.

The deep-dive page Haemorrhoids, Bruising and Topical Use separates what was tested from what is traditional.

Back to Table of Contents

Laboratory Research Beyond Veins

Aescin is an active molecule in the laboratory, and that has produced a long list of headlines that have nothing to do with human evidence:

• Cancer. A 2018 review describes escin slowing growth or killing cancer cells in cell-culture models of lung, liver and blood cancers, and shrinking tumours in animal models. No human cancer trial is described.
• Lung scarring. A 2025 study reported that escin raised levels of a protein called nephronectin and eased experimentally induced lung fibrosis in mice.
• Ion channels. A 2024 review lists escin among natural compounds that block Piezo1, a pressure-sensing channel in cell membranes, in laboratory work.
• Inflammation. A 2025 review of saponins from medicinal plants groups escin with ginsenosides, glycyrrhizin and others as anti-inflammatory compounds in experimental models.

These are early-stage findings in cells and animals. They describe what a purified compound can do to tissue in a dish or a rodent, at doses chosen by researchers, and they say nothing yet about what a supplement does in a person.

Back to Table of Contents

Doses Used in Trials and Monographs

The figures below are reported doses from trials and regulatory documents, not dosing guidance.

• Trials. The Diehm compression trial used extract providing 50 mg aescin twice daily. The EMA report notes that 14 of the trials in the Cochrane review used the same capsule (50 mg aescin, twice daily, 100 mg per day), and two used 75 mg twice daily (150 mg per day). Trial lengths ranged from 2 to 16 weeks.
• EU monograph. The EMA's well-established-use conclusion covers dry ethanolic seed extracts at a daily dose corresponding to 100 mg triterpene glycosides calculated as aescin. The EMA's public summary states that treatment may be needed for at least four weeks before symptoms improve.
• Age. The EMA summary states that the oral medicines are for adults only, and that topical bruise preparations may also be used on the skin in adolescents; its report states that use for bruises is not recommended under 12 years of age because of insufficient safety data.

Raw seeds, homemade conker preparations, bark teas and leaf teas are not the preparations behind any of these figures.

Back to Table of Contents

Safety Findings

In trials of the standardised extract. The Cochrane review found adverse events usually mild and infrequent. NCCIH lists dizziness, digestive upset, headache and itching. The EMA summary lists gastrointestinal disorders, headache, dizziness, itching and allergic reactions by mouth, and skin hypersensitivity reactions with topical use. The Siebert meta-analysis reported no severe adverse events in the trials and observational studies it pooled.

Liver. The National Library of Medicine's LiverTox database rates horse chestnut "D": a possible, rare cause of clinically apparent liver injury. It describes isolated cases appearing 4 to 8 weeks after starting the herb, with a self-limited, rapidly resolving course, and no reported cases of acute liver failure, death or cirrhosis. The EMA report separately describes one 2015 case of liver cirrhosis in a woman who had taken a seed extract for five years, with improvement after stopping, and an older Japanese case after an injected extract.

Kidneys. The EMA report records that a concern about acute kidney failure arose decades ago when heart-surgery patients were given high doses of horse chestnut extract intravenously. Three follow-up clinical studies with 83 participants, including people with existing kidney disease, found no worsening of kidney function at the injected doses tested. The EU monograph keeps a warning that people with heart or kidney insufficiency consult a doctor.

Blood thinners. A 2002 review lists horse chestnut among coumarin-containing herbs that could, in theory, add to bleeding risk with aspirin-type painkillers, while noting that most such interaction data come from individual case reports, animal studies and test-tube work. The EMA report states that aescin has been said to increase the effect of anticoagulants, but that no confirmed case reports were found. It does describe one poorly documented 2012 case of bleeding from a kidney tumour in a woman taking the extract whose INR (a clotting test) was 2.5.

Raw plant. Eating raw seeds causes mainly stomach irritation, but poison-control sources describe more serious reactions in some cases. The details are on the deep-dive page Raw Seed Poisoning and Esculin.

Back to Table of Contents

Who the Research Raises Concerns For

• Pregnancy and breastfeeding. NCCIH states that little is known. The EMA report notes one trial included pregnant women without reported adverse events, but concludes the data are not sufficient, and that reproductive toxicity, genotoxicity and carcinogenicity have not been adequately tested.
• Children. The EU monograph does not cover oral use in anyone under 18. Poison-centre reports also include children who ate raw conkers.
• People on anticoagulants or antiplatelet drugs. The interaction is theoretical and unconfirmed, as described above; it is a question regulators and reviewers have raised.
• People with kidney or heart insufficiency, per the EU monograph's warning.
• People with new, one-sided or sudden leg swelling. The EU monograph names sudden swelling of one or both legs, skin inflammation, thrombophlebitis, severe pain and ulcers as situations for a doctor. Sudden one-sided leg swelling can be a deep-vein clot, which is a medical emergency rather than a vein-tonic question; see Deep Vein Thrombosis.

Decisions about medicines and supplements belong with a clinician who knows the whole picture.

Back to Table of Contents

The Bottom Line

For a herbal medicine, horse chestnut seed extract has an unusually solid core: more than a dozen randomised trials, a Cochrane review updated five times, and European regulatory acceptance, all pointing the same way — a modest, measurable reduction in leg swelling and pain from chronic venous insufficiency over weeks to a few months, with mostly mild side effects. The limits are just as clear: small and short trials, mostly from one standardised extract, no long-term outcome data, and reviews that still call for larger definitive studies. Everything outside chronic venous insufficiency rests on tradition, animals or cell culture. And the raw tree is not the medicine — its seeds, bark and leaves are poisonous to eat.

Back to Table of Contents

Deep-Dive Articles

• Horse Chestnut Benefits Deep Dive — the hub, with an evidence ledger and all the research grouped by theme.
• Chronic Venous Insufficiency Evidence — every version of the Cochrane review, the meta-analysis, and the compression trial.
• Aescin: How It Works — the saponin mixture and the mechanism evidence, layer by layer.
• Raw Seed Poisoning and Esculin — conkers, poison-centre cases, and the esculin question.
• Haemorrhoids, Bruising and Topical Use — the traditional uses and the creams and gels.

Back to Table of Contents

External Sources

• NCCIH: Horse Chestnut — the US National Institutes of Health fact sheet (updated April 2025).
• European Medicines Agency: Hippocastani semen — the EU herbal monograph summary for horse chestnut seed.
• EMA assessment report on horse chestnut seed (2020) — the full evidence review behind the monograph.
• EMA assessment report on horse chestnut bark (2012) — history and chemistry of the bark.
• LiverTox: Horse Chestnut — the National Library of Medicine's liver-injury summary.
• Poison Control: Horse chestnuts are toxic — US National Capital Poison Center article.
• European Atlas of Forest Tree Species: Aesculus hippocastanum — distribution, history and conservation status.

Back to Table of Contents

Key Research Papers

1. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane database of systematic reviews. 2012;11(11):CD003230. PubMed PMID: 23152216
2. Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Archives of dermatology. 1998;134(11):1356-60. PubMed PMID: 9828868
3. Siebert U, Brach M, Sroczynski G, et al.. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. International angiology : a journal of the International Union of Angiology. 2002;21(4):305-15. PubMed PMID: 12518108
4. Diehm C, Trampisch HJ, Lange S, et al.. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet (London, England). 1996;347(8997):292-4. PubMed PMID: 8569363
5. Patel H, Skok C, DeMarco A. Peripheral Edema: Evaluation and Management in Primary Care. American family physician. 2022;106(5):557-564. PubMed PMID: 36379502
6. Gloviczki ML, Kakkos SK, Urbanek T, et al.. The role of venoactive compounds in the treatment of chronic venous disease. Journal of vascular surgery. Venous and lymphatic disorders. 2025;13(5):102258. PubMed PMID: 40348378
7. Bencsik T, Balázs VL, Farkas Á, et al.. Herbal drugs in chronic venous disease treatment: An update. Fitoterapia. 2024;179():106256. PubMed PMID: 39419127
8. Kahn SR. The post-thrombotic syndrome. Hematology. American Society of Hematology. Education Program. 2010;2010():216-20. PubMed PMID: 21239797
9. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacological research. 2001;44(3):183-93. PubMed PMID: 11529685
10. Gallelli L. Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties. Drug design, development and therapy. 2019;13():3425-3437. PubMed PMID: 31631970
11. Wang Y, Han X, Wan X, et al.. β-Escin: An Updated Review of Its Analysis, Pharmacology, Pharmacokinetics, and Toxicity. The American journal of Chinese medicine. 2023;51(8):2095-2120. PubMed PMID: 37865870
12. Cheong DHJ, Arfuso F, Sethi G, et al.. Molecular targets and anti-cancer potential of escin. Cancer letters. 2018;422():1-8. PubMed PMID: 29474858
13. Guo J, Wang Y, Liu Q, et al.. Nephronectin (NPNT) is a Crucial Determinant of Idiopathic Pulmonary Fibrosis: Modulating Cellular Senescence via the ITGA3/YAP1 Signaling Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025;12(32):e01956. PubMed PMID: 40444575
14. Thien ND, Hai-Nam N, Anh DT, et al.. Piezo1 and its inhibitors: Overview and perspectives. European journal of medicinal chemistry. 2024;273():116502. PubMed PMID: 38761789
15. Zheng Q, Wang T, Wang S, et al.. The anti-inflammatory effects of saponins from natural herbs. Pharmacology & therapeutics. 2025;269():108827. PubMed PMID: 40015518
16. Liu J, Li Y, Yuan X, et al.. Sodium beta-aescin may be an effective therapeutic agent for Bell's palsy. Medical hypotheses. 2008;71(5):762-4. PubMed PMID: 18762387
17. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of clinical pharmacy and therapeutics. 2002;27(6):391-401. PubMed PMID: 12472978

PubMed Topic Searches

1. PubMed: horse chestnut seed extract and chronic venous insufficiency
2. PubMed: Aesculus hippocastanum
3. PubMed: aescin (escin)

Back to Table of Contents

Connections

• Heart, Liver and Metabolic Herbs — the category this herb belongs to
• Horse Chestnut: Benefits Deep Dive — the evidence ledger and grouped research
• Chronic Venous Insufficiency Evidence — the trials in detail
• Aescin: How It Works — the saponin and its mechanism
• Raw Seed Poisoning and Esculin — why conkers are not food
• Haemorrhoids, Bruising and Topical Use — creams, gels and traditions
• Varicose Veins — the visible face of venous insufficiency
• Deep Vein Thrombosis — the clot behind post-thrombotic syndrome
• Edema — leg swelling and its many causes
• Hemorrhoids — swollen veins of a different kind
• Lymphedema — swelling from the lymphatic system instead
• How Veins Return Blood (animation) — the calf-muscle pump and failing valves
• Gotu Kola: Venous Insufficiency — another venoactive plant
• Hesperidin: Veins and Circulation — the diosmin–hesperidin flavonoid fraction
• Rutin: Veins and Capillaries — the rutoside comparator
• Pine Bark: Circulation and Veins — a trialled comparator
• Liver Injury from Supplements — the wider picture

Back to top

Featured Videos